Topics

Orchestra BioMed looking to disrupt with high-impact therapeutic solutions in cardiology

08:13 EDT 2 May 2019 | Proactive Investors

Orchestra BioMed Inc Chairman & CEO David Hochman spoke with Proactive Investors at the ThinkEquity Conference in New York. The privately-held Pennsylvania-based biotech is focused on developing therapies to treat cardiovascular health issues like hypertension and atherosclerosis. 

Original Article: Orchestra BioMed looking to disrupt with high-impact therapeutic solutions in cardiology

NEXT ARTICLE

More From BioPortfolio on "Orchestra BioMed looking to disrupt with high-impact therapeutic solutions in cardiology"

Quick Search

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...